Site notifications

Sub menu

 

 

Nicovape Q35 - Coolmint (35 mg/mL) – Notification ID: VG-2024-NTF-00239, Liber Pharmaceuticals Ltd, CON-1379

Product name
Nicovape Q35 - Coolmint (35 mg/mL) – Notification ID: VG-2024-NTF-00239
Sponsor name
Liber Pharmaceuticals Ltd
Consent start
Consent no.
CON-1379
Duration
The consent is effective from 8 July 2025 until the earlier of:
1. 31 July 2025 (inclusive); or
2. when Liber receives notice in writing of the Secretary’s decision in relation to an application for consent to supply.
Standard
One or more of: Section 20; Paragraph (c) in Column 2, Item 2 in the table at subsection 22(1); Items 4, 5 & 6 in the table at subsection 22(1); Item 7 in the table at subsection 23(1); Paragraph (b) in Column 2, Item 8 in the table at subsection 23(1); Paragraph (c) in Column 2, Item 2 in the table at subsection 24(1); Item 6 in the table at subsection 24(1);Section 29; and Paragraph (c) in Column 3, Item 1 of Schedule 1 of Therapeutic Goods (Standard for Nicotine Vaping Products) (TGO 110) Order 2021
Non-compliance with standard
Products do not comply with some requirements of the enhanced product standard for therapeutic vaping goods.
Conditions imposed
Liber must take every reasonable effort to inform each pharmacist, medical practitioner or nurse practitioner (or the practice manager or purchasing officer of that person) who possesses any quantity of the Goods at any time while this consent is effective that: 1. the Goods do not conform with an applicable standard, being TGO 110, from 1 July 2025; 2. the TGA is currently assessing an application from Liber to permit importation and supply of the Goods, despite that non-compliance; and       3. until that application is assessed, the Goods should not be supplied to patients.
Import, Supply, &/or Export
supply
Therapeutic product type
Other therapeutic goods non-approved